Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Charalambos Andreadis, MD, MSCE, UCSF Health, San Francisco, CA, briefly discusses the accessibility challenges faced with CAR T-cell therapy, as this treatment option is only available in specialist centers. Dr Andreadis hopes that with advances in the field, CAR-T will become accessible to a greater proportion of patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Kite/Gilead,BMS, Novartis; Grants or contracts: BMS,Novartis, Genentech; Research Funding: Merck & Co., Inc.